Dear Editor,
We would like to discuss on “Central diabetes insipidus revealing a hypophysitis induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine [1].” Three days after the delivery of the SARS-CoV-2 vaccination, Ach et al. reported an unusual case of hypophysitis with magnetic resonance imaging (MRI) evidence of thickening of the pituitary stalk [1]. Ach et al. hypothesized that an autoimmune/inflammatory syndrome caused by adjuvants was to blame for the delay between symptoms and vaccination receipt in the absence of other possible etiologies [1].
In order to prevent these adverse effects, Ach et al. suggested that additional study be focused on examining the long-term endocrine and autoimmune consequences of the m ribonucleic acid (RNA) coronavirus disease 2019 (COVID-19) vaccination [1].
We both consider receiving the COVID-19 vaccine to be a prudent and secure decision. Co-morbidity can be challenging to manage, thus it's critical to consider any potential risks related to the COVID-19 vaccine [2]. This typically isn’t a good alternative if a clinical problem arises following the vaccination. To avoid any clinical problems, it is crucial to rule out any underlying illnesses or co-morbidities prior to taking a vaccine. Patients with SARS-CoV-2 may not be identified because they show no symptoms. While the effects of other illnesses are uncertain, co-morbidity is occasionally thought to have a detrimental effect [3]. Furthermore, recent studies [4] have connected recipient immunological responses to the COVID-19 with underlying genetic variance. Future studies should consider the diverse genetic background.
Disclosure of interest
The authors declare that they have no competing interest.
Funding source
No funding.
Trial registration
Not applicable.
Data availability statement
Data sharing is not applicable to this article as no new data were created or analyzed in this study.
References
- 1.Ach T., Kammoun F., Fekih H.E., Slama N.B.H., Kahloun S., Fredj F.B., et al. Central diabetes insipidus revealing a hypophysitis induced by SARS-CoV-2 vaccine. Therapie. 2022 doi: 10.1016/j.therap.2022.09.007. S0040-5957(22)00167-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Joob B., Wiwanitkit V. Letter to the editor: coronavirus disease 2019 (COVID-19), infectivity, and the incubation period. J Prev Med Public Health. 2020;53:70. doi: 10.3961/jpmph.20.065. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Kebayoon A., Wiwanitkit V. Dengue after COVID-19 vaccination: possible and might be missed. Clin Appl Thromb Hemost. 2021;27 doi: 10.1177/10760296211047229. 10760296211047229. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Čiučiulkaitė I., Möhlendick B., Thümmler L., Fisenkci N., Elsner C., Dittmer U., et al. GNB3 c.825c>T polymorphism influences T-cell but not antibody response following vaccination with the mRNA-1273 vaccine. Front Genet. 2022;13:932043. doi: 10.3389/fgene.2022.932043. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
Data sharing is not applicable to this article as no new data were created or analyzed in this study.